Clinuvel Pharmaceuticals Limited (CLVLY)
CLVLY Stock Price Chart
Explore Clinuvel Pharmaceuticals Limited interactive price chart. Choose custom timeframes to analyze CLVLY price movements and trends.
CLVLY Company Profile
Discover essential business fundamentals and corporate details for Clinuvel Pharmaceuticals Limited (CLVLY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jan 2008
Employees
—
Website
https://www.clinuvel.comCEO
Philippe Jacques Wolgen
Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
CLVLY Financial Timeline
Browse a chronological timeline of Clinuvel Pharmaceuticals Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Feb 2026
Dividend declared on 8 Sept 2025
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend will be paid on 29 Sept 2025.
Earnings released on 27 Aug 2025
EPS came in at $0.29 surpassing the estimated $0.18 by +57.59%, while revenue for the quarter reached $38.76M , missing expectations by -3.18%.
Earnings released on 26 Feb 2025
EPS came in at $0.18 surpassing the estimated $0.14 by +28.54%, while revenue for the quarter reached $22.30M , beating expectations by +3.16%.
Dividend declared on 9 Sept 2024
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 30 Sept 2024.
Earnings released on 28 Aug 2024
EPS came in at $0.33 surpassing the estimated $0.30 by +10.42%, while revenue for the quarter reached $36.92M , beating expectations by +0.90%.
Earnings released on 22 Feb 2024
EPS came in at $0.14 falling short of the estimated $0.17 by -15.71%, while revenue for the quarter reached $21.96M , missing expectations by -4.76%.
Dividend declared on 30 Aug 2023
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 2 Oct 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.25 falling short of the estimated $0.25 by -2.57%, while revenue for the quarter reached $32.52M , missing expectations by -4.70%.
Earnings released on 31 Dec 2022
EPS came in at $0.15 falling short of the estimated $0.17 by -11.90%, while revenue for the quarter reached $20.06M , missing expectations by -10.75%.
Dividend declared on 2 Sept 2022
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 3 Oct 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.20 falling short of the estimated $0.21 by -6.13%, while revenue for the quarter reached $28.25M , beating expectations by +14.53%.
Earnings released on 31 Dec 2021
EPS came in at $0.08 falling short of the estimated $0.17 by -50.43%, while revenue for the quarter reached $17.85M , beating expectations by +4.86%.
Dividend declared on 1 Sept 2021
A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 27 Sept 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.27 , while revenue for the quarter reached $24.20M .
Earnings released on 31 Dec 2020
EPS came in at $0.10 surpassing the estimated $0.10 by +1.19%, while revenue for the quarter reached $12.07M , beating expectations by +1.19%.
Dividend declared on 4 Sept 2020
A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 28 Sept 2020.
CLVLY Stock Performance
Access detailed CLVLY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.